TOKYO/CAMBRIDGE - The U.S. Food and Drug Administration has accepted Eisai’s application for a subcutaneous autoinjector version of its Alzheimer’s treatment lecanemab-irmb (LEQEMBI) under priority ...

DENVER — Colorado's first-in-the-nation law that allows a state board to limit prescription drug prices is facing a new legal challenge. The pharmaceutical company Amgen is suing the Colorado ...

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...

Colorado finalized the nation’s first prescription drug price cap Oct. 3, establishing an upper payment limit for Enbrel, an autoimmune medication, through the state’s prescription drug affordability ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc.

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen (NASDAQ:AMGN) used certain patent-related tactics to extend its U.S. market dominance ...

Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:AMGN) for extending and entrenching the dominant market position of its blockbuster ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern California ...

Medicare was authorized to negotiate prices it will pay for Part D drugs. Enbrel, the original version of etanercept, was among the first 10 drugs to be subject to negotiations. The negotiated price ...